ES2721228T3 - Formas polimórficas y pseudopolimórfcas del compuesto farmacéutico NXL104 - Google Patents

Formas polimórficas y pseudopolimórfcas del compuesto farmacéutico NXL104 Download PDF

Info

Publication number
ES2721228T3
ES2721228T3 ES17182561T ES17182561T ES2721228T3 ES 2721228 T3 ES2721228 T3 ES 2721228T3 ES 17182561 T ES17182561 T ES 17182561T ES 17182561 T ES17182561 T ES 17182561T ES 2721228 T3 ES2721228 T3 ES 2721228T3
Authority
ES
Spain
Prior art keywords
polymorphic
nxl104
pharmaceutical compound
pseudopolymorphic forms
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17182561T
Other languages
English (en)
Other versions
ES2721228T5 (es
Inventor
Sisir Bhattacharya
Alain Bonnet
Mahendra G Dedhiya
Véronique Ducandas
Alexandre Giuliani
Alain Priour
Valérie Ravaux
Peter Spargo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ireland Pharmaceuticals
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42154208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2721228(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of ES2721228T3 publication Critical patent/ES2721228T3/es
Application granted granted Critical
Publication of ES2721228T5 publication Critical patent/ES2721228T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La sal sódica de (1R,2S,5R)-7-oxo-6-sulfooxi-1,6-diazabiciclo[3.2.1]octano-2-carboxamida de fórmula (I)**Fórmula** en forma cristalizada, anhidra, caracterizada porque la sal está en su forma polimórfica "B", que tiene un patrón de difracción de rayos X con al menos dos picos característicos en 13,0 +/- 0,5 grados 2θ y en 16,5 +/- 0,5 grados 2θ.
ES17182561T 2009-10-09 2010-10-08 Formas polimórficas y pseudopolimórficas del compuesto farmacéutico NXL104 Active ES2721228T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0904864A FR2951171A1 (fr) 2009-10-09 2009-10-09 Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US26366309P 2009-11-23 2009-11-23

Publications (2)

Publication Number Publication Date
ES2721228T3 true ES2721228T3 (es) 2019-07-29
ES2721228T5 ES2721228T5 (es) 2023-10-30

Family

ID=42154208

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10762934.7T Active ES2645110T3 (es) 2009-10-09 2010-10-08 Formas polimórficas y pseudopolimórficas de un compuesto farmacéutico
ES17182561T Active ES2721228T5 (es) 2009-10-09 2010-10-08 Formas polimórficas y pseudopolimórficas del compuesto farmacéutico NXL104

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10762934.7T Active ES2645110T3 (es) 2009-10-09 2010-10-08 Formas polimórficas y pseudopolimórficas de un compuesto farmacéutico

Country Status (22)

Country Link
US (5) US8471025B2 (es)
EP (3) EP3505518A1 (es)
JP (4) JP6072540B2 (es)
KR (4) KR20170134791A (es)
CN (3) CN109824668A (es)
AU (1) AU2010304974B2 (es)
BR (2) BR112012007976B1 (es)
CA (1) CA2716914C (es)
CY (1) CY1121583T1 (es)
DK (1) DK3269717T5 (es)
ES (2) ES2645110T3 (es)
FI (1) FI3269717T4 (es)
FR (1) FR2951171A1 (es)
HU (1) HUE043086T2 (es)
IL (3) IL218565A0 (es)
MX (1) MX2012003730A (es)
MY (1) MY174776A (es)
PL (1) PL3269717T5 (es)
PT (1) PT3269717T (es)
RU (1) RU2727509C2 (es)
SI (1) SI3269717T2 (es)
WO (1) WO2011042560A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096798A1 (en) * 2009-02-23 2010-08-26 Forest Laboratories Holdings Limited Novel cephem compounds useful for the treatment of bacterial infections
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CA2822758C (en) * 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivative and process for preparing the same
US8829191B2 (en) * 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
WO2013014496A1 (en) * 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US8969567B2 (en) 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
WO2013038330A1 (en) * 2011-09-13 2013-03-21 Wockhardt Limited Nitrogen containing compounds and their use
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AU2013268415B2 (en) * 2012-05-30 2017-05-25 Meiji Seika Pharma Co., Ltd. Novel beta-lactamase inhibitor and method for producing same
MX2015011721A (es) * 2013-03-08 2015-12-01 Wockhardt Ltd Proceso para la preparacion de (2s,5r) -7-oxo-6-sulfooxi-2-[((3r)- pirrolidin-3-carbonil) carbonil hidrazino]-1,6-diaza-biciclo[3.2.1 ] octano.
EP3013829A1 (en) * 2013-03-08 2016-05-04 Wockhardt Limited A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
CN105555787B (zh) 2013-09-24 2017-08-08 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法及其中间体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CA2926071C (en) 2013-10-08 2021-11-09 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
EP3107539A1 (en) * 2014-02-20 2016-12-28 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
WO2016066631A1 (en) 2014-10-28 2016-05-06 Sandoz Ag Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution
MX2017006383A (es) 2014-11-17 2017-08-21 Entasis Therapeutics Ltd Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes.
AU2015355970B2 (en) 2014-12-05 2020-05-21 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
JP7075884B2 (ja) * 2015-08-10 2022-05-26 サンド・アクチエンゲゼルシヤフト アビバクタムナトリウムのｃ形
CN107325096B (zh) * 2016-04-29 2020-11-03 正大天晴药业集团股份有限公司 一种阿维巴坦单钠盐的结晶
WO2018037124A1 (en) 2016-08-26 2018-03-01 Sandoz Ag Avibactam free acid
LT3512851T (lt) 2016-09-16 2022-10-25 Entasis Therapeutics Limited Beta-laktamazės inhibitorių junginiai
CN107880042A (zh) * 2016-09-30 2018-04-06 上海复星星泰医药科技有限公司 阿维巴坦钠及其中间体化合物的制备方法
CN110267956B (zh) * 2017-02-08 2022-07-15 桑多斯股份公司 用于制备阿维巴坦钠结晶形式c的方法
DK3630111T3 (en) 2017-05-08 2022-03-14 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
EP3687504A1 (en) * 2017-09-27 2020-08-05 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
CN111465604B (zh) * 2017-09-27 2023-05-12 明治制果药业株式会社 二氮杂二环辛烷衍生物的药物形式及其制备方法
CA3076959A1 (en) * 2017-09-27 2019-04-04 Fedora Pharmaceuticals Inc. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
CN109678856B (zh) 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN107827886B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种高纯度阿维巴坦的精制制备工艺
CN109956941B (zh) 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN107936017A (zh) * 2018-01-12 2018-04-20 上海龙翔生物医药开发有限公司 一种通过结晶制备晶型a或晶型d阿维巴坦产品的方法
CN107935945A (zh) * 2018-01-12 2018-04-20 上海龙翔生物医药开发有限公司 一种通过反应制备晶型a或晶型d阿维巴坦产品的方法
CN110078728B (zh) * 2019-05-23 2020-10-23 江西富祥药业股份有限公司 一种阿维巴坦中间体、制备方法及其应用
CN111689964A (zh) * 2020-07-21 2020-09-22 海南海灵化学制药有限公司 一种阿维巴坦纳的稳定晶型以及制备方法
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737194B1 (en) * 1993-12-29 1999-03-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
TW473479B (en) 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002014333A1 (fr) 2000-08-10 2002-02-21 Takeda Chemical Industries, Ltd. Compose de phosphonocepheme
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
WO2008042227A1 (en) * 2006-09-28 2008-04-10 Med Institute, Inc. Medical device including an anesthetic and method of preparation thereof
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2921559A1 (en) † 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
EP2480236A4 (en) * 2009-09-21 2013-04-17 Astrazeneca Ab COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS USING CEFTAROLINE

Also Published As

Publication number Publication date
HUE043086T2 (hu) 2019-08-28
IL218565A0 (en) 2012-05-31
EP2486038A1 (en) 2012-08-15
US20140349967A1 (en) 2014-11-27
CN109824668A (zh) 2019-05-31
RU2727509C2 (ru) 2020-07-22
JP6072540B2 (ja) 2017-02-01
WO2011042560A1 (en) 2011-04-14
US8835455B2 (en) 2014-09-16
JP6321853B2 (ja) 2018-05-09
ES2645110T3 (es) 2017-12-04
KR20120106720A (ko) 2012-09-26
KR20200010586A (ko) 2020-01-30
IL259296A (en) 2018-07-31
CN102834395A (zh) 2012-12-19
RU2012118247A (ru) 2013-11-20
FI3269717T4 (fi) 2023-08-31
EP3269717B1 (en) 2019-02-27
KR101817811B1 (ko) 2018-01-11
PT3269717T (pt) 2019-05-16
FR2951171A1 (fr) 2011-04-15
US20170210742A1 (en) 2017-07-27
KR20180067717A (ko) 2018-06-20
JP2013507346A (ja) 2013-03-04
AU2010304974A1 (en) 2012-04-05
CN102834395B (zh) 2016-06-29
RU2015137928A3 (es) 2019-04-04
SI3269717T1 (sl) 2019-05-31
US9580424B2 (en) 2017-02-28
MY174776A (en) 2020-05-14
DK3269717T4 (da) 2023-06-26
BR112012007976B1 (pt) 2020-03-03
AU2010304974B2 (en) 2014-10-23
DK3269717T3 (en) 2019-04-23
DK3269717T5 (da) 2023-11-27
BR122019021689B8 (pt) 2021-05-25
US9062053B2 (en) 2015-06-23
EP3269717A1 (en) 2018-01-17
US8471025B2 (en) 2013-06-25
MX2012003730A (es) 2012-10-03
BR122019021689B1 (pt) 2020-10-27
US20110152311A1 (en) 2011-06-23
JP2017149754A (ja) 2017-08-31
IL239663A0 (en) 2015-08-31
CA2716914A1 (en) 2011-04-09
JP6197170B2 (ja) 2017-09-20
US20150246920A1 (en) 2015-09-03
JP2018123151A (ja) 2018-08-09
CA2716914C (en) 2020-10-27
CY1121583T1 (el) 2020-05-29
US20130267480A1 (en) 2013-10-10
JP6630391B2 (ja) 2020-01-15
EP3269717B2 (en) 2023-06-14
PL3269717T5 (pl) 2023-09-18
ES2721228T5 (es) 2023-10-30
PL3269717T3 (pl) 2019-07-31
JP2016029082A (ja) 2016-03-03
EP2486038B1 (en) 2017-08-30
IL259296B (en) 2021-10-31
EP3269717B9 (en) 2023-08-09
SI3269717T2 (sl) 2023-09-29
EP3505518A1 (en) 2019-07-03
RU2015137928A (ru) 2018-12-25
KR20170134791A (ko) 2017-12-06
CN104592229A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
ES2721228T3 (es) Formas polimórficas y pseudopolimórfcas del compuesto farmacéutico NXL104
MX2016006336A (es) Compuestos pirazolopirimidina.
CA2875877C (en) Syk inhibitors
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
BR112013017893A2 (pt) processo de purificação de biphephos e uso de acetato de etila
MA34593B1 (fr) Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
ES2570657T3 (es) Una forma cristalina de hidrocloruro de (R)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato
ECSP11011054A (es) Péptidos antivirales terapéuticos
BR112015021240A2 (pt) processo para sal de sódio de (2s, 5r)-2-carboxamido-7-oxo-6-sulfo-oxi-1,6-diaza-biciclo[3.2.1]octano
EA201270216A1 (ru) Фармацевтический состав
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
CU23757B7 (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
EA201290872A1 (ru) Способ получения бензоксаборолов
WO2011123536A8 (en) Polycyclic tetracycline compounds
BR112012031340A2 (pt) derivados de cianoquinolina
WO2014036502A8 (en) Tetracycline compounds
WO2015070238A3 (en) Coumarin based hsp90 inhibitors with urea and ether substituents
WO2015042414A8 (en) Multicyclic compounds and methods of using same
BR112015022859A2 (pt) processo para fabricação de mono-hidrato trissódico gadofosveset
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
ME00582A (en) Tricyclic compound and pharmaceutical use thereof
GB201020397D0 (en) Compounds